Remove 2014 Remove Communication Remove Insurance
article thumbnail

EC authorises Sydnexis’ paediatric myopia treatment

Pharmaceutical Technology

Founded in 2014, Sydnexis is a US-based company and has recently concluded the three-year primary endpoint of its Phase III trial of the low-dose atropine formulation. Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.

article thumbnail

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Pharmaceutical Technology

The US Food and Drug Administration (FDA) approved Amgen’s Blincyto (blinatumomab), the first bispecific T-cell engager (BiTE), in 2014 for adults with Ph- R/R B-ALL, with its label expanded in 2017 to include Ph+ and paediatric cases. Give your business an edge with our leading industry insights.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top Performing Drug of 2021 - Trulicity (February Edition)

PharmaShots

A qualifying medication is prescribed by their healthcare provider The patients who have no insurance or have Medicare Part D Patients who are not enrolled in Medicaid, full Low-Income Subsidy, or Veterans (VA) benefits. The patient must-have commercial health insurance to use the savings card. mL, 3 mg/0.5 Virgin Islands.

article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

In a manual for hemophilia treatment centers, the agency states it is concerned that providers would have no reason to participate in 340B if insurers take the benefit of 340B savings from them. 2014: HRSA considered publishing a regulation that would have narrowed the definition of patient and placed other restrictions on the program.

article thumbnail

What we’re expecting in 2021, and beyond…

pharmaphorum

While 2014 is often quoted as the first year where the majority of working healthcare professionals were digital natives, 2020 was the year when the remaining digital immigrants were forced to travel into the online world. A growing need for digital health proficiency. The post What we’re expecting in 2021, and beyond… appeared first on.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Novo Nordisk is another company leading the charge in this field.

Labelling 105
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Novo Nordisk is another company leading the charge in this field.